Loading
Every dated change on the records linked to BRAF V600-mutant melanoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
With atezolizumab and vemurafenib in BRAF V600 melanoma
Atezolizumab added to vemurafenib and cobimetinib prolonged investigator-assessed progression-free survival in BRAF V600-mutant melanoma, without an overall survival benefit; approved in July 2020.
A milestone in how this cancer is treated.
BRAF V600 melanoma with binimetinib
Intracranial clinical benefit 57% and complete response 26% in the asymptomatic cohort.
PFS 14.
A milestone in how this cancer is treated.
BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma
Median progression-free survival 12.
Median progression-free survival 11.
A milestone in how this cancer is treated.